FDA panel backs down-classifying HIV drug resistance tests
This article was originally published in Clinica
Executive Summary
A US FDA advisory committee has recommended that HIV genotype drug resistance assays be moved from Class III (high-risk) devices to Class II (medium-risk) devices. Lowering the classification would speed up approval of these products at a time when the ability of the virus to mutate is causing once-successful drugs to fail.